FebriDx Commercial Traction Continues Across US Accounts

Key points

• Lumos expands FebriDx live sites to 215 (previously 170)
• Two new U.S. urgent care groups in top 100 are in network rollout
• Two additional top 100 urgent care groups are progressing with validation

Full summary

Lumos Diagnostics Holdings Ltd is pleased to provide an update on the progress of its U.S. commercialization strategy for FebriDx across its priority top 100 urgent care groups target list. The company has expanded its live sites to 215 and increased the number of sites under evaluation to 405. Two new U.S. urgent care groups within the top 100 have moved into the network rollout stage, while two additional top 100 urgent care groups are progressing with clinical and economic validation. Lumos continues to prioritize the top 100 U.S. urgent care groups, representing an estimated 40% of total U.S. urgent care sites.